Anti Cd 20 Ocrevus denied as duplicate or overlapping therapy by Aetna?

Aetna's specific coverage criteria for anti cd20 ocrevus are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Ocrevus as Duplicate Therapy

Aetna's duplicate-therapy denial means the plan has identified another disease-modifying therapy (DMT) already active on your profile — typically another anti-CD20 agent or a high-efficacy MS therapy — and has concluded the two agents overlap in mechanism or indication. Because Ocrevus (ocrelizumab) targets the CD20 antigen on B cells, Aetna's system may flag it alongside any concurrently authorized DMT, even when the clinical situation calls for a transition rather than a true duplication.

This denial is almost always appealable. Transitions between DMTs — including bridges during washout periods — are standard neurological practice, and a denial that treats an intended switch as ongoing duplication misreads the prescribing intent.

## Federal Appeal Rights

• Internal appeal: You have the right to a full-and-fair internal review under ERISA §503 (employer plans) or applicable state law (individual/small-group plans). Submit within the timeframe noted on your denial letter, typically 180 days.
• External review: Under ACA §2719, if the internal appeal fails you may request an independent external review. The window to file is generally around four months from the final internal denial. An accredited Independent Review Organization (IRO) — not Aetna — makes the binding decision.
• Expedited review: If your neurologist certifies that standard timelines would seriously jeopardize your health, you can request an expedited internal or external review with a compressed turnaround.

## What to Gather

1. Diagnosis confirmation — current MRI reports and neurologist clinic notes establishing relapsing or primary progressive MS and disease activity level. 2. Medication reconciliation — a complete, dated DMT history showing which agent is being stopped, the planned washout timeline, and why Ocrevus is the intended replacement, not an addition. 3. Prescriber letter of medical necessity — your neurologist should explicitly state that this is a therapy switch (or transition), describe why the prior agent was discontinued or is being tapered, and explain why Ocrevus is the appropriate next therapy for this patient. 4. Aetna's current coverage policy — download Aetna's published clinical policy bulletin for ocrelizumab. Map each requirement listed there to a specific chart entry.

## Criteria-Mapping Structure

Copy every criterion from Aetna's policy bulletin and pair each with the corresponding chart fact:

| Policy Requirement | Chart Documentation | |---|---| | Confirmed MS diagnosis (specify type) | Neurology note date + MRI report | | Prior DMT identified | Name, start/stop dates, reason for transition | | Ocrevus is replacement, not addition | Prescriber letter explicitly stating switch intent | | No concurrent high-efficacy DMT remaining active | Medication reconciliation with discontinuation date |

Present this table in your appeal letter so Aetna's reviewer can match each requirement to a page and date in the supporting records.